Hyderabad, India, 6th January, 2026: Pandorum Technologies and Nucelion Therapeutics promises to improve the availability of cutting-edge, exosome-based therapies for patients suffering from ocular diseases in the Asia-Pacific (APAC) region. This strategic partnership is set to expand manufacturing capabilities for Pandorum’s novel regenerative treatment platform, ensuring more efficient production and quicker access to life-changing therapies for those with conditions like corneal injuries, Stevens-Johnson syndrome (SJS), and Neurotrophic Keratitis.
Pandorum Technologies, a clinical-stage regenerative medicine company, is pioneering the use of exosomes, tiny, naturally occurring particles that help repair damaged tissues. Through this collaboration with Nucelion, a Hyderabad-based contract research, development, and manufacturing organization (CRDMO), Pandorum can now scale its production capabilities to meet growing demand in the APAC region. The move will enable quicker, local manufacturing, offering patients better access to therapies that have the potential to restore vision and improve quality of life.
New Ocular Therapy reflects India’s readiness to innovate and manufacture biologics – BIRAC
Dr. Tuhin Bhowmick, CEO of Pandorum Technologies, shared, “As our therapies progress toward clinical trials, establishing strong regional manufacturing infrastructure is essential. Nucelion’s advanced biologics manufacturing expertise allows us to bring our next-generation regenerative treatments closer to patients, ensuring a reliable supply of therapies across APAC.”
The exosome-based treatment, known as Kuragenx, has shown promise in addressing inflammatory corneal diseases and other eye-related injuries. By leveraging Nucelion’s expertise, Pandorum is positioned to bring this innovative therapy to a broader patient population, marking a significant step in regenerative medicine.
Dr. Raghu Malapaka, CBO of Nucelion Therapeutics, added, “We are excited to support Pandorum’s efforts to scale the production of Kuragenx. Our high-quality manufacturing platforms are built to handle complex biologics, and we are committed to ensuring that Pandorum’s therapies are produced at the highest standards for patients across the APAC region.”
In addition to ocular diseases, Pandorum aims to expand its therapeutic reach to other areas, including skin, pulmonary, and organ diseases driven by inflammation, fibrosis, and vascular damage. The collaboration underscores India’s growing leadership in biologics development, further establishing the country as a hub for high-quality, advanced therapeutics.
Dr. Jitendra Kumar, Managing Director of BIRAC, Department of Biotechnology, Govt of India, noted, “This collaboration reflects India’s readiness to innovate and manufacture biologics that address urgent global health needs, reaffirming our capacity to meet the demands of both domestic and international markets.”
Pandorum’s exosome technology works by reprogramming diseased tissues, restoring their natural functions. The company’s unique approach leverages biologically encoded signals delivered through designer exosomes, opening new possibilities for tissue regeneration in a variety of medical conditions.
The strategic partnership with Nucelion Technologies ensures that this revolutionary approach can be scaled, manufactured, and distributed more efficiently, benefiting patients who need these therapies the most.
